January 2010
Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p7
Trade Publication
The article reports on positive initial results posted by Novavax Inc. from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax has partnered with Avimex Laboratories to conduct the study as part of registration of the vaccine in Mexico and other countries. All three dose levels of the vaccine were well-tolerated and showed no systematic side effects.


Related Articles

  • Single dose of influenza A (H1N1) vaccine sufficient for adults.  // Infectious Disease News;Oct2009, Vol. 22 Issue 10, p32 

    The article discusses research being done on the effectiveness of a single dose of influenza A (H1N1) vaccine to protect against the virus in adults by M. Greenberg, published in the 2009 issue of "New England Journal of Medicine."

  • Novavax reports positive results from influenza vaccine study.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p8 

    The article reports that biotechnology company Novavax Inc. reports positive results of its two-state pivotal study to evaluate the safety and immunogenicity of its unadjuvanted 2009 A/H1N1 virus-like particle pandemic influenza vaccine. According to the company, data shows that safety and...

  • A Caution About Giving Tamiflu To Children.  // Child Health Alert;Nov2009, Vol. 27, p4 

    The article discusses research on administering tamiflu to children. It references a study by R. M. Parker et al, published in the September 23, 2009 issue of the "New England Journal of Medicine." It reports the case of a 6-year-old with H1N1 flu who was prescribed with liquid Tamiflu but the...

  • Encephalitis in a child with H1N1 infection: First case report from India. Kulkarni, Rajesh; Kinikar, Aarti // Journal of Pediatric Neurosciences;Jul-Dec2010, Vol. 5 Issue 2, p157 

    Neurological complications have been described with seasonal influenza infection. We report encephalitis manifesting as seizures in a child with confirmed H1N1 infection. Treatment with oseltamivir was started. Child was discharged without any neurological sequelae.

  • Pharmacologic Considerations for Oseltamivir Disposition. Abdel-Rahman, Susan M.; Newland, Jason G.; Kearns, Gregory L. // Pediatric Drugs;2011, Vol. 13 Issue 1, p19 

    Across much of the world, pandemic H1N1 infection has produced a significant healthcare crisis, reflected in significant morbidity and mortality. Statistics reveal that infection-associated deaths among individuals without pre-existing conditions (e.g. immunosuppression) are clustered in...

  • H1N1 dosing and efficacy. Elliott, William T. // Primary Care Reports;Feb2010 Pharmacology Watch, p2 

    The article focuses on the studies that was published in the December 17, 2009 issue of "New England Journal of Medicine," which revealed that a dose of H1N1 vaccine is already effective for those 3 years-old and above. The first study included 240 individuals which were divided to receive 15...

  • Computer-assisted resilience training to prepare healthcare workers for pandemic influenza: a randomized trial of the optimal dose of training. Maunder, Robert G.; Lancee, William J.; Mae, Reet; Vincent, Leslie; Peladeau, Nathalie; Beduz, Mary Agnes; Hunter, Jonathan J.; Leszcz, Molyn // BMC Health Services Research;2010, Vol. 10, p72 

    Background: Working in a hospital during an extraordinary infectious disease outbreak can cause significant stress and contribute to healthcare workers choosing to reduce patient contact. Psychological training of healthcare workers prior to an influenza pandemic may reduce stress-related...

  • Characterization of Functional Antibody and Memory B-Cell Responses to pH1N1 Monovalent Vaccine in HIV-Infected Children and Youth. Curtis, Donna J.; Muresan, Petronella; Nachman, Sharon; Fenton, Terence; Richardson, Kelly M.; Dominguez, Teresa; Flynn, Patricia M.; Spector, Stephen A.; Cunningham, Coleen K.; Bloom, Anthony; Weinberg, Adriana // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Objectives: We investigated immune determinants of antibody responses and B-cell memory to pH1N1 vaccine in HIV-infected children. Methods: Ninety subjects 4 to <25 years of age received two double doses of pH1N1 vaccine. Serum and cells were frozen at baseline, after each vaccination, and at...

  • Meeting the Demand for Vaccine Production.  // Pharmaceutical Processing;Jun2010, Vol. 25 Issue 6, p42 

    The article focuses on the partnership between Novartis Pharmaceuticals Corp. and ITT Pure-Flo to provide assurance that Novartis could meet all H1N1 pandemic vaccine demand requirements in the U.S. It notes that Andrew Mahoney, channel relationship manager at ITT Pure- Flo, was contracted to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics